Vizsgálati helyszín
Calvary Mater Newcastle Hospital
Waratah, New South Wales 2298, AusztráliaMég nincs intézményhez kötve
- 18futó vizsgálat
- 4lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 22 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis11 vizsgálat
- 1. fázis4 vizsgálat
- 2. fázis4 vizsgálat
- 1/2. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Toboroz9 vizsgálat
- Fut, nem toboroz8 vizsgálat
- Lezárult3 vizsgálat
- Még nem toboroz1 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Amgen6 vizsgálat
- Janssen Research & Development, LLC5 vizsgálat
- Canadian Cancer Trials Group2 vizsgálat
- Eikon Therapeutics2 vizsgálat
- Alliance Foundation Trials, LLC.1 vizsgálat
- és még 6
Futó vizsgálatok
Toboroz
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07365319· 2/3. fázis· Eikon Therapeutics· Forrás
Contact: Elelta Shiferraw
Toboroz
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619· 1/2. fázis· Eikon Therapeutics· Forrás
Contact: Ana C Mamede, PharmD
Toboroz
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674· 3. fázis· Amgen· Forrás
Fut, nem toboroz
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
NCT07140900· 1. fázis· Amgen· Forrás
Fut, nem toboroz
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522· 2. fázis· Amgen· Forrás
Toboroz
A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma
NCT06768489· 1. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
NCT06598306· 1. fázis· Amgen· Forrás
Toboroz
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314· 3. fázis· Immunocore Ltd· Forrás
Contact: MOR Clinical Trials
Toboroz
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135· 3. fázis· Kartos Therapeutics, Inc.· Forrás
Contact: John Mei
Fut, nem toboroz
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083· 3. fázis· Stichting European Myeloma Network· Forrás
Fut, nem toboroz
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566· 3. fázis· Amgen· Forrás
Toboroz
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT05640999· 2. fázis· Canadian Cancer Trials Group· Forrás
Contact: Geetha Govindarajulu
Toboroz
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
NCT05169177· University of Sydney· Forrás
Contact: Principal Investigator
Fut, nem toboroz
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT04722146· 1. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT02947685· 3. fázis· Alliance Foundation Trials, LLC.· Forrás
Toboroz
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
NCT02821013· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Ina Nordman
Fut, nem toboroz
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251· 2. fázis· Karyopharm Therapeutics Inc· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek